Enspire DBS Therapy raises $10.3M Series B1 — RESTORE pivotal DBS + stroke rehab trial enrolling, EDEN results in Nature Medicine
Summary
Enspire DBS Therapy announced on January 13, 2026 the raising of $10.3 million in a Series B1 financing led by Genesys Capital, with participation from existing investors Cleveland Clinic and JobsOhio Ventures. The capital funds continued enrollment in RESTORE — the multicenter pivotal Phase 2/3 clinical trial evaluating deep brain stimulation combined with structured rehabilitation (DBS + Rehab) for chronic upper-extremity impairment due to stroke. RESTORE is the first pivotal trial of DBS for stroke rehabilitation and is designed to generate the long-term safety and effectiveness data required for FDA marketing authorization. Interim results are expected mid-2027. Enspire also published EDEN — its early feasibility trial of DBS + Rehab for stroke — in Nature Medicine. CEO Scott Kokones stated the financing "represents an important milestone as we advance RESTORE through pivotal clinical development."
Why it matters
Deep brain stimulation for stroke arm recovery is a genuinely novel indication — DBS has never been used for rehabilitation augmentation before. The EDEN Nature Medicine publication provides the peer-reviewed foundation that convinced Cleveland Clinic to co-invest alongside Genesys Capital. If RESTORE's interim data shows upper-extremity motor improvement, Enspire would have the first DBS therapy for stroke rehabilitation — a multi-billion dollar indication where no device-based therapy currently exists.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial